Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets.
Endometrial cancer
Fos
Janus kinase (JAK)
Jun
Platelet derived growth factor receptor (PDGFR)
Progesterone receptor (PR)
Signal transducer and activator of transcription (STAT)
Journal
The Journal of steroid biochemistry and molecular biology
ISSN: 1879-1220
Titre abrégé: J Steroid Biochem Mol Biol
Pays: England
ID NLM: 9015483
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
31
07
2023
revised:
06
09
2023
accepted:
12
09
2023
medline:
6
11
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
Progesterone prevents development of endometrial cancers through its receptor (PR) although the molecular mechanisms have yet to be fully characterized. In this study, we performed a global analysis of gene regulation by progesterone using human endometrial cancer cells that expressed PR endogenously or exogenously. We found progesterone strongly inhibits multiple components of the platelet derived growth factor receptor (PDGFR), Janus kinase (JAK), signal transducer and activator of transcription (STAT) pathway through PR. The PDGFR/JAK/STAT pathway signals to control numerous downstream targets including AP-1 transcription factors Fos and Jun. Treatment with inhibitors of the PDGFR/JAK/STAT pathway significantly blocked proliferation in multiple novel patient-derived organoid models of endometrial cancer, and activation of this pathway was found to be a poor prognostic signal for the survival of patients with endometrial cancer from The Cancer Genome Atlas. Our study identifies this pathway as central to the growth-limiting effects of progesterone in endometrial cancer and suggests that inhibitors of PDGFR/JAK/STAT should be considered for future therapeutic interventions.
Identifiants
pubmed: 37716459
pii: S0960-0760(23)00154-1
doi: 10.1016/j.jsbmb.2023.106399
pii:
doi:
Substances chimiques
Janus Kinases
EC 2.7.10.2
Progesterone
4G7DS2Q64Y
STAT Transcription Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106399Subventions
Organisme : NCI NIH HHS
ID : F31 CA210610
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA263783
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA265793
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG008974
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest KWT is a cofounder of Immortagen, Inc. All others authors delcar they have no financial interests.